

VGI Health Technology Limited enters into R&D Loan Facility Agreement with Fundsquire Pty Ltd

Sydney, New South Wales, 13 October 2022 – VGI Health Technology Limited (**NSX:VTL or the Company**) is pleased to announce that it has entered into an R&D Loan Facility Agreement (**Loan Facility**) with Fundsquire Pty Ltd (**Fundsquire**). The Loan Facility allows up to 80% of VTL's expected R&D Tax Refund in FY23 to be advanced to VTL by Fundsquire and the first drawdown of \$209,500.00 on this Loan Facility has been received by the Company.

Dr Glenn Tong, the CEO and Managing Director of VTL said "We are very pleased to have access to this Loan Facility which will facilitate the advancement of our clinical development program, and in particular, our two Phase II Clinical Studies in Non-Alcoholic Fatty Liver Disease and Pancreatic Adenocarcinoma".

For more information please contact:

Dr Glenn Tong, CEO and Managing Director
Ph: +61 (0) 412 193 350

Mrs Catriona Glover, Company Secretary
Tel: +61 (0) 402 328 200

About VGI Health Technology Limited

VGI Health Technology Limited trading as VGI Health Technology is an Australian public listed company (NSX:VTL). VTL refers to recent announcements about the divestment of its wholly owned subsidiary Invictus BioPharma Pty Ltd. Post completion of this transaction, VTL will be focussed on manufacturing, marketing and selling novel dietary supplements based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery and exercise endurance. The Company has a product development program for evidence-based nutraceuticals.

For more information see: <https://www.vgiht.com>

Investors interested in trading shares on the NSX should contact a broker who is an NSX Participant:
https://www.nsx.com.au/broker_list_print.asp